CA2941140A1 - Traitement de lesions resistantes - Google Patents

Traitement de lesions resistantes Download PDF

Info

Publication number
CA2941140A1
CA2941140A1 CA2941140A CA2941140A CA2941140A1 CA 2941140 A1 CA2941140 A1 CA 2941140A1 CA 2941140 A CA2941140 A CA 2941140A CA 2941140 A CA2941140 A CA 2941140A CA 2941140 A1 CA2941140 A1 CA 2941140A1
Authority
CA
Canada
Prior art keywords
connexin
lesion
subject
resistant
modulating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2941140A
Other languages
English (en)
Inventor
David Eisenbud (Deceased)
Anthony Phillips
Scott BANNAN
Grove MATSUOKA
Bradford DUFT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CoDa Therapeutics Inc
Original Assignee
CoDa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CoDa Therapeutics Inc filed Critical CoDa Therapeutics Inc
Publication of CA2941140A1 publication Critical patent/CA2941140A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés et des compositions de modulation de la connexine pour la cicatrisation de lésions résistantes, y compris des lésions chez des sujets souffrant de multiples ulcères veineux de jambe ou de multiples ulcères du pied diabétique, et d'autres sujets répondant. L'invention concerne également des kits et des articles de fabrication comprenant un agent de modulation de la connexine, par exemple, un agent de modulation de la connexine 43 pour une utilisation dans la cicatrisation de lésions résistantes.
CA2941140A 2014-03-14 2015-03-16 Traitement de lesions resistantes Abandoned CA2941140A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461953604P 2014-03-14 2014-03-14
US201461953608P 2014-03-14 2014-03-14
US61/953,608 2014-03-14
US61/953,604 2014-03-14
PCT/US2015/020786 WO2015139047A2 (fr) 2014-03-14 2015-03-16 Traitement de lésions résistantes

Publications (1)

Publication Number Publication Date
CA2941140A1 true CA2941140A1 (fr) 2015-09-17

Family

ID=54072608

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2941140A Abandoned CA2941140A1 (fr) 2014-03-14 2015-03-16 Traitement de lesions resistantes

Country Status (3)

Country Link
EP (1) EP3116996A4 (fr)
CA (1) CA2941140A1 (fr)
WO (1) WO2015139047A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0721094A2 (pt) * 2006-12-11 2014-02-11 Coda Therapeutics Inc Composições e tratamentos de cicatrização de ferida prejudicada
AU2008335717A1 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
JP2011507855A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 外科的癒着の治療のための、単独のまたは抗コネキシンポリヌクレオチドと組み合わせた抗コネキシンペプチドの使用
WO2013058778A1 (fr) * 2010-11-01 2013-04-25 Nanoderm Sciences, Inc. Polymères et hydrogels
US9156896B2 (en) * 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments

Also Published As

Publication number Publication date
WO2015139047A3 (fr) 2015-12-10
EP3116996A2 (fr) 2017-01-18
EP3116996A4 (fr) 2018-01-10
WO2015139047A2 (fr) 2015-09-17

Similar Documents

Publication Publication Date Title
US20100279921A1 (en) Impaired wound healing compositions and treatments
RU2521329C2 (ru) Композиции и способы лечения плохо заживающих ран
US20110038920A1 (en) Wound healing compositions and treatments
US20110300130A1 (en) Impaired wound healing compositions and treatments
KR20100027091A (ko) 상처 치유를 위한 개선 방법 및 조성물
JP2015057430A (ja) 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用
US20170056468A1 (en) Treatment of resistant lesions
WO2013148736A1 (fr) Compositions et traitements basés sur la modulation de la cadhérine
US20180028468A1 (en) Sustained release drug delivery devices
CA2940648A1 (fr) Traitement des lesions resistantes
US20160244759A1 (en) Compositions and treatments based on cadherin modulation
CA2941140A1 (fr) Traitement de lesions resistantes
AU2017202281A1 (en) Impaired wound healing compositions and treatments

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211123

FZDE Discontinued

Effective date: 20211123